News All News

Harvard launched a new licensing model across three technology pathways: Engineering & Technology, Medical Device, and Software, to help academic innovators turn promising ideas into real-world products faster and more efficiently. 

Scaling biomanufacturing is often constrained by how efficiently gases move through liquids—FluxBio, a Harvard startup out of the lab of Jarad Mason in the Department of Chemistry & Chemical Biology at Harvard, found a solution by re-engineering the liquid, not the machine. The microporous water technology received critical early support from the Blavatnik Biomedical Accelerator to advance while in the lab and ultimately form the basis for FluxBio.

Harvard Magazine’s Q&A with Leonardo Riella, the HMS Harold and Ellen Danser Associate Professor of Surgery at Massachusetts General Hospital, on the advancement of xenotransplantation. Reilla discusses what the research and medical teams learned from the first successful kidney transplant using a genetically engineered pig kidney developed by eGenesis, a company founded by HMS Professor George Church and former HMS postdoctoral fellow Luhan Yang with support from the Wyss Institute.

Connie Cepko reflects on four decades of advancing efforts to prevent or treat vision-threatening disease. The Cepko Lab is highly translational, advancing research with support from the Blavatnik Biomedical Accelerator and by collaborating with industry, resulting in over 40 inventions from the lab.